Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brodalumab - AstraZeneca/Bausch Health Companies/Kyowa Kirin/LEO Pharma

Drug Profile

Brodalumab - AstraZeneca/Bausch Health Companies/Kyowa Kirin/LEO Pharma

Alternative Names: AMG-827; KHK-4827; Kyntheum; LP 0160; LUMICEF; SILIQ; Siliq

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Developer Amgen; AstraZeneca; Bausch Health Companies; Kyowa Hakko Kirin; Kyowa Kirin; LEO Pharma
  • Class Anti-inflammatories; Antiasthmatics; Antipsoriatics; Antirheumatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 17 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ankylosing spondylitis; Axial spondyloarthritis; Erythrodermic psoriasis; Palmoplantar pustulosis; Plaque psoriasis; Psoriasis; Psoriatic arthritis; Pustular psoriasis
  • Preregistration Systemic scleroderma
  • Discontinued Asthma; Crohn's disease; Rheumatoid arthritis

Most Recent Events

  • 23 Aug 2023 Launched for Palmoplantar pustulosis (Treatment-experienced) in Japan (SC)
  • 23 Aug 2023 Registered for Palmoplantar pustulosis (Treatment-experienced) in Japan (SC)
  • 30 Jun 2023 Registered for Ankylosing spondylitis in Thailand (SC) (Kyowa Kirin pipeline, August 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top